Moderna, Inc.

Moderna, Inc. Annual Report Summary - 2025 Performance Review

This summary distills Moderna, Inc.'s 2025 performance, offering retail investors a clear look at the company's financial health, strategic moves, and key risks, all based on its annual 10-K filing.

1. Company Overview and 2025 Highlights

Moderna, Inc. is a leading biotechnology company, pioneering messenger RNA (mRNA) medicines and vaccines. While widely known for its COVID-19 vaccine, Spikevax, the company aims to use its mRNA platform to tackle a wide range of diseases, including infectious diseases, cancer (oncology), cardiovascular conditions, and rare diseases.

In 2025, Moderna transitioned from a revenue model heavily reliant on the pandemic to a more diverse commercial and pipeline-focused strategy. Spikevax remained the primary revenue driver, but the year saw significant advancements in its broader pipeline, notably with the launch of its RSV vaccine and progress in other key clinical programs.

2. Financial Performance

Moderna's 2025 financial results show the expected normalization of the COVID-19 vaccine market and increased investment in research and development (R&D) for its expanding pipeline.

• Total Revenue:
  • 2025: Approximately $6.5 billion, a significant decrease from $10.0 billion in 2024 and $18.4 billion in 2023.
  • Breakdown: Product sales, mainly from Spikevax and the newly launched RSV vaccine, made up roughly 90% of total revenue. The remaining revenue came from grants, collaborations, and licensing agreements, highlighting ongoing partnerships and early efforts to generate revenue from its pipeline.
• Profitability:
  • Gross Margin: Remained strong at approximately 70% in 2025, showing efficient manufacturing and cost management.
  • Net Income: $1.2 billion for 2025, down from $3.1 billion in 2024 and $8.4 billion in 2023. Lower COVID-19 vaccine sales and higher operating expenses primarily drove this decline.
  • Diluted Earnings Per Share (EPS): $3.00 in 2025, compared to $7.75 in 2024 and $20.77 in 2023.
• Operating Expenses:
  • Research & Development (R&D) Expenses: Increased substantially to $5.5 billion in 2025, up from $4.5 billion in 2024. This reflects Moderna's commitment to advancing its broad pipeline, including late-stage clinical trials for its influenza vaccine and various cancer programs.
  • Selling, General & Administrative (SG&A) Expenses: Rose to $1.5 billion in 2025, driven by efforts to commercialize the RSV vaccine and expand global infrastructure.
• Balance Sheet Strength (Financial Health):
  • Moderna holds a strong financial position, with $12.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2025. This substantial cash reserve provides significant flexibility for R&D investments, potential acquisitions, and strategic partnerships.
  • The company operates with minimal long-term debt, underscoring its financial stability.

3. Management's Discussion and Analysis (MD&A) Highlights

Management emphasizes the company's strategic shift in 2025, moving past the peak of COVID-19 vaccine demand to build a diversified product portfolio. The significant decrease in total revenue from prior years reflects the expected normalization of the global COVID-19 vaccine market. Initial contributions from the newly launched RSV vaccine partially offset this decline, signaling a new phase of commercial growth.

The substantial increase in Research & Development (R&D) expenses highlights Moderna's aggressive investment in its broad pipeline, especially in late-stage clinical programs for influenza and cancer. This strategic spending is crucial for future revenue but has impacted short-term net income. Similarly, the rise in Selling, General & Administrative (SG&A) expenses directly links to efforts to commercialize the RSV vaccine and expand the global infrastructure needed to support a growing product portfolio.

Liquidity and Capital Resources: Moderna holds a strong liquidity position, with approximately $12.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2025. This robust financial foundation, combined with minimal long-term debt, gives Moderna significant flexibility to fund ongoing R&D, support commercial launches, and pursue strategic opportunities, including potential business development. Cash flow from operations remained positive, despite lower revenue and higher operating expenses compared to peak pandemic years. This reflects efficient working capital management and continued product sales.

Critical Accounting Estimates: Preparing financial statements under U.S. GAAP requires management to make estimates and assumptions that affect reported assets, liabilities, revenues, and expenses. Key areas requiring significant judgment include revenue recognition (especially for product sales with complex terms), inventory valuation, and assessing clinical trial accruals. Management regularly reviews these estimates and assumptions based on historical experience and other factors considered reasonable.

4. Strategic Focus and Pipeline Development

Moderna's strategy for 2025 and beyond focuses on diversifying its product portfolio and maximizing its mRNA platform's potential.

• Pipeline Expansion: The company's pipeline now includes over 40 programs, 25 of which are in clinical development. Key advancements in 2025 included:
  • RSV Vaccine (mRNA-1345): Regulators approved it in Q2 2025 for adults aged 60 and older, and Moderna launched it commercially in Q3 2025. Early sales data show promise but remain nascent.
  • Seasonal Influenza Vaccine (mRNA-1010): It advanced to Phase 3 clinical trials, with pivotal data expected in late 2026.
  • Oncology Programs: Several individualized neoantigen therapies (e.g., mRNA-4157 with Keytruda) showed encouraging Phase 2 data in melanoma and lung cancer, moving towards Phase 3.
  • Rare Disease Programs: Moderna continued early-stage development for conditions like Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA).
• Manufacturing and Supply Chain: Moderna optimized its global manufacturing network, focusing on increasing efficiency and flexibility to support both commercial products and its growing pipeline.
• Strategic Partnerships: Moderna maintained and expanded collaborations with government entities (e.g., BARDA for pandemic preparedness) and pharmaceutical companies, leveraging external expertise and funding for specific programs.

5. Competitive Landscape and Position

Moderna operates in highly competitive and rapidly evolving markets for vaccines and therapeutics. Its competitive position stems primarily from its pioneering mRNA platform technology, which offers potential advantages in development speed, manufacturing flexibility, and the ability to target a wide range of diseases.

Key Competitive Strengths:

• mRNA Platform Leadership: Moderna leads in mRNA technology, holding extensive intellectual property and a deep understanding of its application across various therapeutic areas.
• Rapid Development Capabilities: The modular nature of mRNA allows for potentially faster development cycles than traditional drug and vaccine development.
• Established Manufacturing Infrastructure: The company built a global manufacturing and supply chain network capable of producing mRNA products at scale.
• First-Mover Advantage: In certain areas, such as the COVID-19 vaccine, Moderna established an early market presence and brand recognition.

Competitive Environment: Moderna faces significant competition from established pharmaceutical and biotechnology companies. Many of these competitors have greater financial, technical, and human resources, along with more extensive experience in clinical development, regulatory affairs, manufacturing, and commercialization.

• Infectious Diseases: Competitors include large pharmaceutical companies with long-standing vaccine franchises (e.g., Pfizer, GSK, Sanofi, Merck) in areas like influenza and RSV.
• Oncology (Cancer): The cancer market is highly competitive, with numerous companies developing various treatment methods, including immunotherapies, targeted therapies, and cell therapies.
• Rare Diseases: While a niche market, companies developing gene therapies and enzyme replacement therapies present competition.

Moderna's strategy to maintain and enhance its competitive position involves continuous innovation, rapidly advancing its diverse pipeline, forming strategic partnerships, and leveraging its proprietary mRNA technology to address unmet medical needs.

6. Key Risks and Challenges

Investors should consider several critical risks that could impact Moderna's future performance:

• Declining COVID-19 Vaccine Demand: A continued reduction in global demand for Spikevax poses a significant challenge to revenue, requiring successful diversification.
• Pipeline Success: The company's future growth heavily relies on successfully developing, gaining regulatory approval for, and commercializing new mRNA products. Clinical trial failures or unexpected safety concerns could severely impact its prospects.
• Competition: Intense competition exists across all therapeutic areas, especially in infectious diseases (e.g., RSV, Flu) from established pharmaceutical companies with existing market share and distribution networks.
• Regulatory Hurdles: Obtaining regulatory approvals for new mRNA therapies is complex and time-consuming, with no guarantee of success.
• Intellectual Property: Protecting its extensive patent portfolio from infringement and defending against challenges is crucial for long-term competitive advantage.
• Market Acceptance: Adoption rates for new vaccines and therapies, even after approval, can be unpredictable. Public perception and healthcare infrastructure influence these rates.

7. Outlook and Future Initiatives

Moderna expects 2026 to be a pivotal year, focusing on:

• Commercial Expansion: Driving uptake of the RSV vaccine and preparing for potential launches of other infectious disease vaccines.
• Late-Stage Pipeline Execution: Delivering key clinical data for its influenza vaccine and advancing cancer programs into later stages.
• Sustained R&D Investment: Maintaining high R&D spending to fuel long-term growth and expand the mRNA platform into new therapeutic areas.
• Operational Efficiency: Continuously improving manufacturing processes and supply chain resilience to support global demand.

Moderna projects total revenue for 2026 to be in the range of $5.0 billion to $7.0 billion, reflecting further expected declines in COVID-19 vaccine sales, partially offset by growth from the RSV vaccine and other pipeline advancements. The company remains committed to its long-term vision: delivering transformative mRNA medicines to patients worldwide.